STRIDES PHARMA SCIENCE LTD (STAR): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹1,002.2 latest close · −11.1% over the last 90 sessions

₹1,002.2 month-end · +14.1% over 12 months

₹1,002.2 month-end · +130.5% over 3 years

₹1,002.2 month-end · +143.1% since Jan '19

52-week range ₹768.65 to ₹1260.90 · 1-year volatility 36.6%

Was the rally earned?

1 year5 years

+14%share price, 1 yearLower P/E held it back

Mostly yes, with a catch.

Per-share earnings added 63 points, but investors now pay less per rupee of profit (P/E 23.7x to 15.1x), which took 48 points back.
The share count barely moved.

Net profit growth+62 ptsNet profit rose about 79%, which lifts the price.

P/E change-48 ptsThe P/E fell from 23.7x to 15.1x, which lowers the price.

Share count change+1 ptsShare count was little changed. More shares would count against the price.

+130%share price, 5 yearsEarnings-driven

Mostly yes.

Per-share earnings added 125 points to the rise, while the multiple moved less (P/E 14.6x to 15.1x).
The share count rose 10%.

Net profit growth+140 ptsNet profit rose about 145%, which lifts the price.

P/E change+5 ptsThe P/E rose from 14.6x to 15.1x, which lifts the price.

Share count change-15 ptsShare count rose 10%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-72.6%recovered 2024-06

1-year volatility36.6%annualised

Beta vs sector index1.273-year daily, correlation 0.37

Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-72.6% (2021-01 peak to 2022-05 low, recovered 2024-06)

-61.1% (2024-10 peak to 2025-01 low, not yet recovered)

-50.0% (2019-01 peak to 2020-03 low, recovered 2020-08)

Most recent volume spikes

2026-10-30: 11.4x the 50-day median, price -2.6% that day

2026-09-07: 13.9x the 50-day median, price +11.2% that day

2026-08-20: 29.7x the 50-day median, price +3.7% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

15.1xP/E todayWithin its usual range

Against its own history52nd percentile

CheapestMedian 14.6xDearest

Usual range 3.7x to 164.2x since 2019-01.

Against Health Technology15.1x vs 37.0x

This company

15.1x

Sector median

37.0x

59% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE66th▲ 16 pts vs a year ago
Op. margin55thflat vs a year ago
Revenue growth34th▼ 33 pts vs a year ago
EPS growth86th▲ 79 pts vs a year ago
Debt/equity ↓18th▲ 7 pts vs a year ago
Cash cycle ↓49thflat vs a year ago
P/E ↓84th▲ 13 pts vs a year ago
12M momentum58th▲ 40 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~11%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 14.1x, a holder earning 12%/yr needs earnings to grow about 11.3%/yr for 10 years, then trade at 15x.

Delivered15.4%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg

Gap−4.1 ptsimplied minus delivered

Rank614thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	12.8%	13.8%	14.8%
15x	10.3%	11.3%	12.3%
20x	7.2%	8.1%	9.1%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 11.3%/yr

Looking back

Jan 2020Price implied 4%/yr; EPS has since grown 8%/yr (7.0 yrs)
Jan 2021Price implied 13%/yr; EPS has since grown 62%/yr (6.0 yrs)
Jan 2022Price implied 5%/yr; EPS has since grown 17%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹1002.20
P/E: 15.1x
ROCE: 18.0%
Market Cap: ₹9235 cr
Revenue (TTM): ₹5004 cr
P/S: 1.8x
P/B: 3.0x
ROE: 19.7%
Operating Margin: 18.0%
Debt / Equity: 0.6x
Promoter Holding: 27.9%
12M Momentum: 14.1%

52-week range

₹768.65₹1260.90

47% of the way from its 52-week low to its high

Price risk

1Y volatility

36.6%

Beta vs sector

1-year daily

1.02

Balance sheet & cash

Interest cover

operating profit ÷ interest

5.3x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.51x

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 7checks within range4 near a threshold

Other income reliance26%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 25.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate15%Within range

Median quarterly effective tax rate over about 2.5 years: 15.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.51xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.51x (cash from operations ₹2,088 cr, net profit ₹4,079 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-10 daysWithin range

Debtor days are below the median of the previous three fiscal years by 10 days (97 vs 107). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress21% of fixed assetsWithin range

Capital work-in-progress is 21% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+66 days / 2 yrsNear threshold

Days payable changed by +66 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, FIIs added 11.1 pts; DIIs trimmed 4.1 pts.
The number of shareholders fell from 1.0 lakh to 94,850 (-7%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters27.8%27.9%+0.1 pts

FIIs17.3%28.4%+11.1 pts

DIIs19.5%15.4%-4.1 pts

Public and others35.1%28.3%-6.8 pts

Number of shareholders

94,850shareholders-7% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−16.4%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like STRIDES PHARMA SCIENCE LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −30% to +3% vs the market, against −3% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −13.3%, 80% range −20.5% to −7.1%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−16.4%

All companies' median

−3.1%

Beat the market

30% vs 47%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
BIRLACORPN Non-Energy Minerals	Aug 2021	17x	12%	+120%	−10%	−33%
ORIENTCEM Non-Energy Minerals	Aug 2021	15x	19%	+134%	−10%	−26%
FSL Commercial Services	Oct 2023	21x	15%	+50%	−9%	+57%
EPL Process Industries	Jun 2025	22x	17%	+23%	−15%	−8%
JKLAKSHMI Non-Energy Minerals	Jan 2023	19x	19%	+31%	−17%	−9%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GRANULES Health Technology	Nov 2024	29x	15%	+46%	−19%	−8%
WELENT Industrial Services	Nov 2024	25x	18%	+61%	−13%	−5%
DCMSHRIRAM Process Industries	Mar 2021	11x	19%	+133%	−10%	+83%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/S and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to STRIDES PHARMA SCIENCE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

EPLEPL

Process Industries

82%similar

ROCErevenue

EDELWEISS FINANCIAL SERVICES LEDELWEISS

Finance

62%similar

promoter holdingmarket cap

TIME TECHNOPLASTTIMETECHNO

Process Industries

61%similar

market capvolatility

IIFL CAPITAL SERVICESIIFLCAPS

Finance

59%similar

debt/equitypromoter holding

NCCNCC

Consumer Durables

59%similar

promoter holdingmarket cap

GRANULES INDIAGRANULES

Health Technology

57%similar

revenuepromoter holding

NATCO PHARMANATCOPHARM

Health Technology

51%similar

volatilityP/E

MARKSANS PHARMAMARKSANS

Health Technology

44%similar

ROCEmarket cap

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Sep '23

2026
OctPriceVolume reached 11.4x its 50-day median on 2026-10-30; price -2.6% that day.
SepResultsYear-on-year EPS growth turned positive.
SepPeer rankMoved into the top quartile of Health Technology on EPS growth (from the bottom quartile).
AugPriceVolume reached 29.7x its 50-day median on 2026-08-20; price +3.7% that day.
JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
MayPriceVolume reached 6.6x its 50-day median on 2026-05-18; price -0.2% that day.
AprPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
JanPriceVolume reached 18.9x its 50-day median on 2026-01-30; price +8.3% that day.

Show 22 earlier events

2025
OctPriceVolume reached 45.0x its 50-day median on 2025-10-31; price +9.7% that day.
SepResultsYear-on-year EPS growth turned negative.
JunInstitutionsFII + DII holding fell 6.3 pts over 2 quarters to 42.0%.
JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the bottom quartile).
JunDebtDebt / equity fell below 1.0x (0.74x).
JunDividendStarted paying a dividend (payout 1% of profit).
MayPriceVolume reached 9.5x its 50-day median on 2025-05-29; price +9.3% that day.
MarValuationP/E fell below the 10th percentile of its own history to date (1.7x).
MarPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
JanPriceFell 61% from the Oct 2024 peak to the Jan 2025 low.
JanPriceVolume reached 10.8x its 50-day median on 2025-01-01; price +6.8% that day.
2024
DecPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
SepResultsEPS (TTM) turned positive.
SepValuationP/E fell below the 10th percentile of its own history to date (3.5x).
JulPriceVolume reached 6.3x its 50-day median on 2024-07-29; price +0.8% that day.
JunResultsRevenue (TTM) reached a new high of ₹3,890 cr.
JunPriceRegained the 2021-01 peak, 25 months after the low.
JunInstitutionsFII + DII holding rose 5.5 pts over 2 quarters to 42.2%.
MayPriceVolume reached 10.4x its 50-day median on 2024-05-22; price +6.3% that day.
JanPriceVolume reached 11.3x its 50-day median on 2024-01-02; price +3.4% that day.
2023
DecPriceVolume reached 13.7x its 50-day median on 2023-12-11; price +5.0% that day.
SepPriceVolume reached 19.0x its 50-day median on 2023-09-15; price +5.5% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	15.1x	₹5004 cr	19.7%	18.0%	0.6x
2026-10	16.1x	₹5004 cr	19.8%	18.0%	0.6x
2026-09	16.8x	₹5004 cr	19.8%	18.0%	0.6x
2026-08	17.0x	₹4859 cr	17.9%	18.0%	0.6x
2026-07	17.0x	₹4859 cr	17.9%	18.0%	0.6x
2026-06	18.1x	₹4859 cr	17.9%	18.0%	0.6x
2026-05	20.0x	₹4726 cr	20.2%	15.0%	0.7x
2026-04	18.7x	₹4726 cr	20.2%	15.0%	0.7x
2026-03	16.9x	₹4726 cr	20.2%	15.0%	0.7x
2026-02	19.8x	₹4685 cr	15.7%	15.0%	0.7x
2026-01	20.4x	₹4685 cr	15.7%	15.0%	0.7x
2025-12	20.9x	₹4685 cr	15.7%	15.0%	0.7x
2025-11	23.7x	₹4631 cr	13.5%	15.0%	0.7x
2025-10	25.2x	₹4631 cr	13.5%	15.0%	0.7x
2025-09	22.1x	₹4631 cr	13.5%	15.0%	0.7x
2025-08	2.2x	₹4565 cr	136.7%	15.0%	0.7x
2025-07	2.2x	₹4565 cr	136.7%	15.0%	0.7x
2025-06	2.3x	₹4565 cr	136.7%	15.0%	0.7x
2025-05	2.1x	₹4419 cr	160.6%	7.0%	1.2x
2025-04	1.7x	₹4419 cr	160.6%	7.0%	1.2x
2025-03	1.7x	₹4419 cr	160.6%	7.0%	1.2x
2025-02	—	₹4271 cr	159.0%	7.0%	1.2x
2025-01	—	₹4271 cr	159.0%	7.0%	1.2x
2024-12	—	₹4271 cr	159.0%	7.0%	1.2x
2024-11	4.1x	₹4103 cr	148.9%	7.0%	1.2x
2024-10	3.9x	₹4103 cr	148.9%	7.0%	1.2x
2024-09	3.5x	₹4103 cr	148.9%	7.0%	1.2x
2024-08	—	₹3890 cr	-4.3%	7.0%	1.2x
2024-07	—	₹3890 cr	-4.3%	7.0%	1.2x
2024-06	—	₹3890 cr	-4.3%	7.0%	1.2x
2024-05	—	₹3688 cr	-9.3%	0.0%	1.4x
2024-04	—	₹3688 cr	-9.3%	0.0%	1.4x
2024-03	—	₹3688 cr	-9.3%	0.0%	1.4x
2024-02	—	₹3688 cr	-9.3%	0.0%	1.4x
2024-01	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-12	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-11	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-10	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-09	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-08	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-07	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-06	—	₹3688 cr	-9.3%	0.0%	1.4x
2023-05	—	₹3070 cr	-19.5%	-5.0%	1.3x
2023-04	—	₹3070 cr	-19.5%	-5.0%	1.3x
2023-03	—	₹3070 cr	-19.5%	-5.0%	1.3x
2023-02	—	₹3070 cr	-19.5%	-5.0%	1.3x
2023-01	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-12	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-11	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-10	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-09	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-08	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-07	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-06	—	₹3070 cr	-19.5%	-5.0%	1.3x
2022-05	9.9x	₹3316 cr	9.0%	8.0%	0.8x
2022-04	9.8x	₹3316 cr	9.0%	8.0%	0.8x
2022-03	10.3x	₹3316 cr	9.0%	8.0%	0.8x
2022-02	9.6x	₹3316 cr	9.0%	8.0%	0.8x
2022-01	11.8x	₹3316 cr	9.0%	8.0%	0.8x
2021-12	13.3x	₹3316 cr	9.0%	8.0%	0.8x
2021-11	14.6x	₹3316 cr	9.0%	8.0%	0.8x
2021-10	16.0x	₹3316 cr	9.0%	8.0%	0.8x
2021-09	17.6x	₹3316 cr	9.0%	8.0%	0.8x
2021-08	18.3x	₹3316 cr	9.0%	8.0%	0.8x
2021-07	23.0x	₹3316 cr	9.0%	8.0%	0.8x
2021-06	22.7x	₹3316 cr	9.0%	8.0%	0.8x
2021-05	168.5x	₹2752 cr	1.2%	5.0%	0.9x
2021-04	190.3x	₹2752 cr	1.2%	5.0%	0.9x
2021-03	185.9x	₹2752 cr	1.2%	5.0%	0.9x
2021-02	183.5x	₹2752 cr	1.2%	5.0%	0.9x
2021-01	179.2x	₹2752 cr	1.2%	5.0%	0.9x
2020-12	193.3x	₹2752 cr	1.2%	5.0%	0.9x
2020-11	168.2x	₹2752 cr	1.2%	5.0%	0.9x
2020-10	151.9x	₹2752 cr	1.2%	5.0%	0.9x
2020-09	158.3x	₹2752 cr	1.2%	5.0%	0.9x
2020-08	133.0x	₹2752 cr	1.2%	5.0%	0.9x
2020-07	96.0x	₹2752 cr	1.2%	5.0%	0.9x
2020-06	90.1x	₹2752 cr	1.2%	5.0%	0.9x
2020-05	9.8x	₹2178 cr	12.1%	2.0%	1.2x
2020-04	10.9x	₹2178 cr	12.1%	2.0%	1.2x
2020-03	7.9x	₹2178 cr	12.1%	2.0%	1.2x
2020-02	11.6x	₹2178 cr	12.1%	2.0%	1.2x
2020-01	11.4x	₹2178 cr	12.1%	2.0%	1.2x
2019-12	8.9x	₹2178 cr	12.1%	2.0%	1.2x
2019-11	9.5x	₹2178 cr	12.1%	2.0%	1.2x
2019-10	9.5x	₹2178 cr	12.1%	2.0%	1.2x
2019-09	7.6x	₹2178 cr	12.1%	2.0%	1.2x
2019-08	9.4x	₹2178 cr	12.1%	2.0%	1.2x
2019-07	9.5x	₹2178 cr	12.1%	2.0%	1.2x
2019-06	9.8x	₹2178 cr	12.1%	2.0%	1.2x
2019-05	5.1x	₹2845 cr	26.9%	16.0%	1.0x
2019-04	5.8x	₹2845 cr	26.9%	16.0%	1.0x
2019-03	5.7x	₹2845 cr	26.9%	16.0%	1.0x
2019-02	5.1x	₹2845 cr	26.9%	16.0%	1.0x
2019-01	5.6x	₹2845 cr	26.9%	16.0%	1.0x

Methodology and data notes